Acquired by Danaher in Dec 2023
Company logo

ABCM - Abcam plc

NASDAQ -> Healthcare -> Biotechnology
Cambridge, United Kingdom
Type: Equity

ABCM price evolution
ABCM
(in millions $) 30 Jun 2023 31 Mar 2023 31 Dec 2022 30 Sep 2022
Current assets
Cash $79 $79 $89 $89
Short term investments
Net receivables $108.6 $108.6 $90.3 $90.3
Inventory $66.3 $66.3 $68 $68
Total current assets $255.8 $255.8 $255.4 $255.4
Long term investments $3.5 $3.5 $3.2 $3.2
Property, plant & equipment $157.5 $157.5 $159.7 $159.7
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $1027.1 $1027.1 $1056.6 $1056.6
Current liabilities
Accounts payable $61.4 $61.4 $15.8 $15.8
Deferred revenue
Short long term debt $127.5 $127.5 $128.1 $128.1
Total current liabilities $188.9 $188.9 $201.8 $201.8
Long term debt $89.5 $89.5 $95.8 $95.8
Total noncurrent liabilities
Total debt
Total liabilities $307.9 $307.9 $329.7 $329.7
Shareholders' equity
Retained earnings $326.4 $326.4 $300.7 $300.7
Other shareholder equity $124.6 $124.6 $158.2 $158.2
Total shareholder equity $719.2 $719.2 $726.9 $726.9
(in millions $) 31 Dec 2022 31 Dec 2021 30 Jun 2020 30 Jun 2019
Current assets
Cash $89 $95.1 $187.3 $87.1
Short term investments
Net receivables $90.3 $52.6 $46.1 $43.4
Inventory $68 $58.2 $40.7 $36
Total current assets $255.4 $211.5 $278.8 $171.8
Long term investments $3.2 $3.5 $7 $0.8
Property, plant & equipment $159.7 $161.7 $164.7 $37.1
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $1056.6 $986.1 $811.4 $446.7
Current liabilities
Accounts payable $15.8 $12.9 $9.4 $7
Deferred revenue
Short long term debt $128.1 $128.4 $113.7
Total current liabilities $201.8 $187.2 $159.6 $45.3
Long term debt $95.8 $101.3 $120.5
Total noncurrent liabilities
Total debt
Total liabilities $329.7 $330 $308.8 $61.9
Shareholders' equity
Retained earnings $300.7 $358.2 $324.3 $328.2
Other shareholder equity $158.2 $31.3 $42.2 $32
Total shareholder equity $726.9 $656.1 $502.6 $384.8
(in millions $) 30 Jun 2023 31 Mar 2023 31 Dec 2022 30 Sep 2022
Revenue
Total revenue $101.6 $101.6 $88.25 $88.25
Cost of revenue $24.15 $24.15 $21.65 $21.65
Gross Profit $77.45 $77.45 $66.6 $66.6
Operating activities
Research & development $9.8 $9.8 $8 $8
Selling, general & administrative $49.05 $49.05 $40.7 $40.7
Total operating expenses $83 $83 $70.35 $70.35
Operating income $18.6 $18.6 $17.9 $17.9
Income from continuing operations
EBIT
Income tax expense $3.3 $3.3 -$4.35 -$4.35
Interest expense -$2.6 -$2.6 -$1.95 -$1.95
Net income
Net income $8.4 $8.4 -$7.15 -$7.15
Income (for common shares) $8.4 $8.4 -$7.15 -$7.15
(in millions $) 31 Dec 2022 31 Dec 2021 30 Jun 2020 30 Jun 2019
Revenue
Total revenue $361.7 $462.9 $260 $259.9
Cost of revenue $88.5 $133.7 $79.8 $76.7
Gross Profit $273.2 $329.2 $180.2 $183.2
Operating activities
Research & development $35.1 $30.4 $17.4 $10.7
Selling, general & administrative $184.3 $235.4 $118.3 $88.9
Total operating expenses $307.9 $438.5 $249.5 $203.8
Operating income $53.8 $24.4 $10.5 $56.1
Income from continuing operations
EBIT
Income tax expense -$7.1 $3.1 -$4.1 $11.2
Interest expense -$5.9
Net income
Net income -$8.5 $17.2 $12.5 $45
Income (for common shares) -$8.5 $17.2 $12.5 $45
(in millions $) 30 Jun 2023 31 Mar 2023 31 Dec 2022 30 Sep 2022
Net income $8.4 $8.4 -$7.15 -$7.15
Operating activities
Depreciation $6.15 $6.15 $9.2 $9.2
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations $13.65 $13.65 -$0.55 -$0.55
Investing activities
Capital expenditures -$4.85 -$4.85 -$6.15 -$6.15
Investments
Total cash flows from investing -$10.5 -$10.5 -$5.25 -$5.25
Financing activities
Dividends paid
Sale and purchase of stock $0.15 $0.15 $0.25 $0.25
Net borrowings -$2.7 -$2.7 -$2.8 -$2.8
Total cash flows from financing -$5.9 -$5.9 -$4.1 -$4.1
Effect of exchange rate
Change in cash and equivalents -$5 -$5 -$10.3 -$10.3
(in millions $) 31 Dec 2022 31 Dec 2021 30 Jun 2020 30 Jun 2019
Net income -$8.5 $24.4 $10.5 $56.1
Operating activities
Depreciation $43.8 $28.2 $14 $4.8
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations $28.7 $96.2 $63 $70.2
Investing activities
Capital expenditures -$16.8 -$84.3 -$35.7 -$40.4
Investments
Total cash flows from investing -$24.4 -$313.7 -$148.1 -$49.9
Financing activities
Dividends paid -$25 -$24.9
Sale and purchase of stock $0.9 $130.1 $111.1 $1.2
Net borrowings -$11.3 $0.4 $100.2
Total cash flows from financing -$15.5 $126.4 $184.6 -$24.7
Effect of exchange rate -$1.1 $0.7 $1.3
Change in cash and equivalents -$6.1 -$92.2 $100.2 -$3.1
News
Reasons Why Danaher (DHR) Should be in Your Portfolio Now
Zacks via Yahoo Finance 12 Apr 2024
Danaher (DHR) Acquires Abcam to Boost Life Sciences Segment
Zacks via Yahoo Finance 7 Dec 2023
GMED or ABCM: Which Is the Better Value Stock Right Now?
Zacks · via Yahoo Finance 20 Nov 2023
Druckenmiller, Soros Cut Stakes in Nvidia After Share Surge
Bloomberg via Yahoo Finance 15 Nov 2023
George Soros' Major Moves: Spotlight on iShares iBoxx USD Investment Grade Corporate Bond ETF
GuruFocus.com via Yahoo Finance 15 Nov 2023
Here’s Headwaters Capital’s Perspective on Abcam plc (ABCM) Acquisition
Insider Monkey via Yahoo Finance 15 Nov 2023
Meta Platforms Inc Takes a Hit in Jeremy Grantham's Latest Portfolio Adjustments
GuruFocus.com via Yahoo Finance 13 Nov 2023
Here’s Why Baron Discovery Fund Sold Abcam plc (ABCM)
Insider Monkey via Yahoo Finance 9 Nov 2023
Here’s Why Abcam plc (ABCM) Rose in Q2
Insider Monkey via Yahoo Finance 22 Sep 2023
FLGB ETF: British Blue Chips Look A Fair Deal
Seeking Alpha 19 Sep 2023
Fundamentals
Market cap N/A
Enterprise value N/A
Shares outstanding N/A
Revenue $379.70M
EBITDA N/A
EBIT N/A
Net Income $2.50M
Revenue Q/Q 9.72%
Revenue Y/Y -24.15%
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA 0.24%
ROE 0.35%
Debt/Equity 0.45
Net debt/EBITDA N/A
Current ratio 1.35
Quick ratio 1.00